NK-1 Receptor Antagonists: Who Truly Need them and their Cost-Effectiveness Analysis?
- *Corresponding Author:
- Akihito Kubo
Department of Respiratory Medicine and Allergology
Aichi Medical University School of Medicine 1-1 Yazakokarimata
Nagakute, Aichi 480-1195, Japan
E-mail: [email protected]
Received date: February 09, 2016; Accepted date: March 14, 2016; Published date: March 21, 2016
Citation: Kubo A, Tsukiyama I, Tsukiyama S, Ejiri M, Matsuura K, et al. (2016) NK-1 Receptor Antagonists: Who Truly Need them and their Cost- Effectiveness Analysis?. Chemo Open Access 5:197. doi:10.4172/2167-7700.1000197
Copyright: © 2016 Akihito K, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Chemotherapy Induced Nausea and Vomiting (CINV) remains a major adverse effect of chemotherapy. While the incidence of CINV is declining with the development of antiemetic agents and improvement in various guidelines for the prevention and treatment of CINV, it still has a serious impact on cancer patients’ well-being and adherence to chemotherapy.